CAMP4 Therapeutics (NASDAQ:CAMP) Stock Picked Up by Analysts at Needham & Company LLC

Needham & Company LLC assumed coverage on shares of CAMP4 Therapeutics (NASDAQ:CAMP) in a research report issued on Thursday, Benzinga reports. The brokerage set a “buy” rating and a $8.00 price target on the Wireless communications provider’s stock. Needham & Company LLC’s price target would suggest a potential upside of 133.24% from the company’s previous close.

Other analysts have also issued reports about the company. Piper Sandler reaffirmed an “overweight” rating and issued a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Weiss Ratings downgraded CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. Zacks Research raised CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th. Cantor Fitzgerald reissued an “overweight” rating on shares of CAMP4 Therapeutics in a report on Tuesday, September 29th. Finally, Oppenheimer assumed coverage on shares of CAMP4 Therapeutics in a research note on Monday, October 5th. They issued an “outperform” rating and a $15.00 price target on the stock. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, CAMP4 Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.50.

CAMP4 Therapeutics Price Performance

CAMP stock opened at $3.43 on Thursday. The business’s 50 day simple moving average is $4.17 and its 200 day simple moving average is $4.19. CAMP4 Therapeutics has a 1-year low of $2.86 and a 1-year high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. The company had revenue of $1.78 million during the quarter. As a group, analysts anticipate that CAMP4 Therapeutics will post -0.66 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Kelly Gold purchased 10,000 shares of the company’s stock in a transaction dated Monday, August 31st. The stock was bought at an average cost of $3.96 per share, for a total transaction of $39,600.00. Following the purchase, the chief financial officer owned 10,000 shares of the company’s stock, valued at approximately $39,600. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard A. Young acquired 16,378 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were purchased at an average cost of $1.65 per share, for a total transaction of $27,023.70. Following the acquisition, the director owned 186,388 shares in the company, valued at $307,540.20. This represents a 9.63% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have purchased 46,031 shares of company stock valued at $99,051 and have sold 593,613 shares valued at $2,504,037. Insiders own 21.69% of the company’s stock.

Hedge Funds Weigh In On CAMP4 Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CAMP. Jupiter Topco LLC bought a new position in CAMP4 Therapeutics in the second quarter valued at about $27,581,000. 5AM Venture Management LLC acquired a new stake in shares of CAMP4 Therapeutics during the second quarter valued at about $25,647,928. Trails Edge Capital Partners LP bought a new stake in shares of CAMP4 Therapeutics during the second quarter worth about $8,446,935. BlackRock Inc. bought a new stake in shares of CAMP4 Therapeutics during the second quarter worth about $7,185,000. Finally, SummitTX Capital L.P. bought a new stake in shares of CAMP4 Therapeutics during the first quarter worth about $1,497,000.

CAMP4 Therapeutics Company Profile

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing RNA-based medicines for genetic diseases caused by insufficient production of essential proteins. The company’s approach is designed to increase expression of a patient’s existing genes rather than replace or edit them.

CAMP4 uses its RegRNA platform to identify regulatory elements in messenger RNA and develop RNA activators, including small activating RNAs, that may stimulate production of targeted proteins.